Freestone Capital Holdings’s Arbutus Biopharma ABUS Stock Holding History

Freestone Capital Holdings’s Portfolio ABUS Stock Details ABUS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.12M	Hold	442,500	–	–	0.06%	194
2026 Q1	$1.99M	Hold	442,500	–	–	0.06%	184
2025 Q4	$2.13M	Hold	442,500	–	–	0.06%	174
2025 Q3	$2.01M	Hold	442,500	–	–	0.06%	182
2025 Q2	$1.37M	Hold	442,500	–	–	0.05%	201
2025 Q1	$1.54M	Hold	442,500	–	–	0.06%	180
2024 Q4	$1.45M	Sell	442,500 -700	-0.2%	-$2.58K	0.05%	187
2024 Q3	$1.71M	Sell	443,200 -103,052	-19%	-$395K	0.06%	175
2024 Q2	$1.69M	Buy	+546,252	New	+$1.64M	0.06%	175

Other funds holding ABUS

TSC

Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

WCM

Whitefort Capital Management New York $406M AUM 84.26% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Freestone Capital Holdings's ABUS Position: Q2 2026 in Review

Freestone Capital Holdings held its Arbutus Biopharma (ABUS) position steady in Q2 2026 at 442,500 shares worth $2.12M. The position accounts for 0.06% of the portfolio, ranked #194.

Freestone Capital Holdings first reported a position in ABUS in Q2 2024 and has held it in 9 quarters since. The position peaked at $2.13M in Q4 2025. 177 funds tracked by Wall St. Rank hold ABUS as of Q2 2026.

Freestone Capital Holdings held 442,500 shares of Arbutus Biopharma worth $2.12M as of Q2 2026.
Freestone Capital Holdings left its Arbutus Biopharma share count unchanged in Q2 2026.
Arbutus Biopharma made up 0.06% of Freestone Capital Holdings's portfolio in Q2 2026, its #194 holding.
Freestone Capital Holdings first reported a position in Arbutus Biopharma in Q2 2024 and has held it in 9 quarters since.
Freestone Capital Holdings's Arbutus Biopharma position peaked at $2.13M in Q4 2025.
177 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q2 2026.

Based on Freestone Capital Holdings's 13F filing for Q2 2026, filed 31 Jul 2026.